Literature DB >> 11021797

Molecular and neuronal substrate for the selective attenuation of anxiety.

K Löw1, F Crestani, R Keist, D Benke, I Brünig, J A Benson, J M Fritschy, T Rülicke, H Bluethmann, H Möhler, U Rudolph.   

Abstract

Benzodiazepine tranquilizers are used in the treatment of anxiety disorders. To identify the molecular and neuronal target mediating the anxiolytic action of benzodiazepines, we generated and analyzed two mouse lines in which the alpha2 or alpha3 GABAA (gamma-aminobutyric acid type A) receptors, respectively, were rendered insensitive to diazepam by a knock-in point mutation. The anxiolytic action of diazepam was absent in mice with the alpha2(H101R) point mutation but present in mice with the alpha3(H126R) point mutation. These findings indicate that the anxiolytic effect of benzodiazepine drugs is mediated by alpha2 GABAA receptors, which are largely expressed in the limbic system, but not by alpha3 GABAA receptors, which predominate in the reticular activating system.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021797     DOI: 10.1126/science.290.5489.131

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  251 in total

1.  Glutamic acid decarboxylase and glutamate receptor changes during tolerance and dependence to benzodiazepines.

Authors:  E Izzo; J Auta; F Impagnatiello; C Pesold; A Guidotti; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

Review 2.  Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety.

Authors:  Xia Chen; Joop van Gerven; Adam Cohen; Gabriel Jacobs
Journal:  Acta Pharmacol Sin       Date:  2018-12-05       Impact factor: 6.150

3.  Reduction of fear-potentiated startle by benzodiazepines in C57BL/6J mice.

Authors:  Kiersten S Smith; Edward G Meloni; Karyn M Myers; Ashlee Van't Veer; William A Carlezon; Uwe Rudolph
Journal:  Psychopharmacology (Berl)       Date:  2010-10-05       Impact factor: 4.530

4.  Presynaptic alpha2-GABAA receptors in primary afferent depolarization and spinal pain control.

Authors:  Robert Witschi; Pradeep Punnakkal; Jolly Paul; Jean-Sébastien Walczak; Fernando Cervero; Jean-Marc Fritschy; Rohini Kuner; Ruth Keist; Uwe Rudolph; Hanns Ulrich Zeilhofer
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

Review 5.  GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam.

Authors:  Raman Sankar
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 6.  A novel GABA(A) receptor pharmacology: drugs interacting with the α(+) β(-) interface.

Authors:  Werner Sieghart; Joachim Ramerstorfer; Isabella Sarto-Jackson; Zdravko Varagic; Margot Ernst
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

7.  Apremilast regulates acute effects of ethanol and other GABAergic drugs via protein kinase A-dependent signaling.

Authors:  Yuri A Blednov; Cecilia M Borghese; Michael P Dugan; Swetak Pradhan; Thanvi M Thodati; Nikhita R Kichili; R Adron Harris; Robert O Messing
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

8.  Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys.

Authors:  Angela N Duke; Zhiqiang Meng; Donna M Platt; John R Atack; Gerard R Dawson; David S Reynolds; V V N Phani Babu Tiruveedhula; Guanguan Li; Michael Rajesh Stephen; Werner Sieghart; James M Cook; James K Rowlett
Journal:  J Pharmacol Exp Ther       Date:  2018-05-02       Impact factor: 4.030

Review 9.  GABAA receptor polymorphisms in alcohol use disorder in the GWAS era.

Authors:  Mairi Koulentaki; Elias Kouroumalis
Journal:  Psychopharmacology (Berl)       Date:  2018-05-02       Impact factor: 4.530

10.  GABAA receptor alpha5 subunits contribute to GABAA,slow synaptic inhibition in mouse hippocampus.

Authors:  Ewa D Zarnowska; Ruth Keist; Uwe Rudolph; Robert A Pearce
Journal:  J Neurophysiol       Date:  2008-12-10       Impact factor: 2.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.